Long-standing mammography computer-aided detection company whose ProFound AI was the first cleared for 3D mammography; acquired by RadNet in July 2025.
iCAD, based in Nashua, New Hampshire, and founded in 1984, is a long-standing mammography computer-aided detection company whose ProFound AI was the first AI cleared for three-dimensional mammography, and RadNet completed its acquisition through its DeepHealth subsidiary on 17 July 2025. It moved from classical CAD to deep learning with ProFound AI, cleared by the FDA in 2018 for tomosynthesis, added breast density and risk products, and now sits alongside DeepHealth and Kheiron in RadNet's portfolio. OnCo links it to breast cancer, AI in radiology and mammography and tomosynthesis, and to the ProFound AI product record. Whether consolidation of breast AI under one imaging provider speeds adoption or narrows choice is the open question. ProFound AI has its own page.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · Acquisition by RadNet through its DeepHealth subsidiary, completed 17 July 2025; the closing release does not state a total value | 2025 | undisclosed | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
The first AI cleared for 3D mammography in the US, now part of RadNet's imaging network.
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
Commercial and regulated products that this organisation sells. Each card says what is behind it: a regulator's database, the literature, a public body's list, or only the company's own words. Listing is not endorsement, and a clearance is a regulatory fact, not a clinical one.
Detection and density software for digital breast tomosynthesis and mammography, marking lesions and giving a case score.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/